8-K: Coherus Oncology Reports Strong LOQTORZI Growth

Coherus Oncology reported a 36% increase in LOQTORZI net revenue for Q2 2025, reaching $10.0 million, alongside strategic debt reduction and extended cash runway through 2026.

Summary

• LOQTORZI net revenue for Q2 2025 was $10.0 million, a 36% increase compared to Q1 2025's $7.3 million, and significantly up from $3.8 million in Q2 2024.
• The growth in LOQTORZI revenue was primarily driven by higher patient demand and some inventory restocking, supported by its preferred status in NCCN guidelines for nasopharyngeal carcinoma (NPC).
• Net income from discontinued operations, net of tax, was $342.6 million for Q2 2025, largely due to a $339.1 million net gain from the UDENYCA divestiture completed on April 11, 2025.
• The UDENYCA divestiture generated $483.4 million in cash, including $118.4 million for product inventory, with potential for up to $75 million in additional milestone payments.
• Proceeds from the UDENYCA sale were used to repay substantially all of the $230 million aggregate principal amount of outstanding 2026 Convertible Notes and buy out UDENYCA royalty rights for $47.7 million.
• Cash, cash equivalents, and marketable securities totaled $237.6 million as of June 30, 2025, up from $126.0 million at December 31, 2024.
• Research and development (R&D) expenses from continuing operations increased to $26.3 million in Q2 2025 from $20.6 million in Q2 2024, primarily due to increased costs for casdozokitug and CHS-114 development.
• Selling, general and administrative (SG&A) expenses from continuing operations decreased to $26.0 million in Q2 2025 from $27.5 million in Q2 2024, driven by lower headcount and reduced operating costs following recent divestitures.
• Net loss from continuing operations for Q2 2025 was $44.9 million, or $(0.39) per diluted share, an improvement from a net loss of $54.9 million, or $(0.48) per diluted share, in Q2 2024.
• The company maintains a cash runway through 2026, extending beyond key data readouts for its pipeline programs.

Sentiment

Score: 8

Explanation: The sentiment is highly positive due to strong commercial growth of the key oncology product (LOQTORZI), successful divestiture of a non-core asset leading to significant cash inflow, substantial debt reduction, and an extended cash runway. The progress of the oncology pipeline with upcoming data readouts further contributes to a positive outlook, despite ongoing operational losses from continuing operations.

Positives

• LOQTORZI net revenue increased by 36% quarter-over-quarter to $10.0 million in Q2 2025, indicating strong commercial execution and market adoption.
• The completion of the UDENYCA divestiture generated $483.4 million in cash, significantly strengthening the company's financial position.
• Substantially all of the $230 million 2026 Convertible Notes were repaid, reducing debt obligations and improving the balance sheet.
• The company bought out UDENYCA royalty rights for $47.7 million, eliminating future royalty payments on that product.
• Cash, cash equivalents, and marketable securities increased to $237.6 million by June 30, 2025, providing a cash runway through 2026.
• Net loss from continuing operations improved to $44.9 million in Q2 2025 from $54.9 million in Q2 2024.
• Pipeline clinical programs (CHS-114 and casdozokitug) are progressing and on track for data readouts in 1H 2026, potentially derisking the pipeline and unlocking market potential.

Negatives

• Research and development expenses from continuing operations increased to $26.3 million in Q2 2025 from $20.6 million in Q2 2024, reflecting higher development costs.
• Non-GAAP net loss from continuing operations increased to $39.0 million in Q2 2025 from $34.7 million in Q2 2024.
• Accrued rebates, fees, and reserves totaled $96.8 million as of June 30, 2025, primarily UDENYCA-related obligations that did not transfer and are expected to be settled over the remainder of 2025 and into 2026.

Risks

• Risks and uncertainties inherent in the clinical drug development process.
• Dependence on the ability to raise funds in the future, which may not be available on acceptable terms or at all.
• Risks related to existing and potential collaboration partners.
• Risks of the company's competitive position.
• Risks and uncertainties of the regulatory approval process, including the speed of regulatory review and the timing of regulatory filings.
• Risk of FDA review issues.
• Risks and uncertainties of possible litigation.
• A majority of the $96.8 million in accrued rebates, fees and reserves reflected on the June 30, 2025 balance sheet are UDENYCA-related obligations that did not transfer in the divestiture and are expected to be settled in a front-loaded fashion over the remainder of the year and into 2026.

Future Outlook

The company expects continued strong clinical execution to derisk its pipeline, unlocking large U.S. market potential and creating ex-U.S. licensing opportunities as clinical data for CHS-114 and casdozokitug evolve. Initial data readouts for these pipeline candidates are on track for the first half of 2026. The company also anticipates anti-CCR8s, like CHS-114, to potentially become a new treatment backbone broadly across solid tumor types in 2026.

Management Comments

• "We are executing well commercially, and our focus on maximizing LOQTORZIs potential in nasopharyngeal carcinoma has resulted in a 36% net revenue increase over Q1 2025 to $10.0 million."
• "With cash runway through 2026, beyond key data readouts, continued strong clinical execution will derisk the pipeline, unlocking large U.S. market potential and creating Ex-U.S. licensing opportunities as the clinical data further evolve."
• "Our pipeline clinical programs with CHS-114 and casdozkitug in solid tumors are progressing and on track for data readouts in 2026."
• "We believe that in 2026, anti-CCR8s may start to realize their therapeutic promise and become a new treatment backbone, used broadly across solid tumor types."

Industry Context

The company's focus on oncology, particularly with its PD-1 inhibitor LOQTORZI and next-generation pipeline candidates like CHS-114 (CCR8 antibody) and casdozokitug (IL-27 antagonist), aligns with the broader industry trend towards developing targeted immunotherapies for various solid tumors. The emphasis on combination therapies (e.g., LOQTORZI with internal pipeline candidates) reflects a common strategy to enhance efficacy and expand indications in the competitive oncology landscape. The divestiture of non-core assets like UDENYCA allows for a sharper focus on the oncology pipeline, a strategic move seen across the biotech sector to streamline operations and allocate capital to high-growth areas.

Comparison to Industry Standards

• No specific comparable companies, projects, or results are mentioned in the filing to provide a direct assessment against global benchmarks.

Stakeholder Impact

• **Shareholders:** Positive impact from increased cash reserves, significant debt reduction, and strong growth in LOQTORZI revenue. The strategic focus on oncology and pipeline progression could enhance long-term value. The net income from discontinued operations significantly boosted overall reported earnings per share.
• **Patients:** Continued availability and increased adoption of LOQTORZI for nasopharyngeal carcinoma, and ongoing development of new oncology treatments (CHS-114, casdozokitug) for various solid tumors, potentially offering new therapeutic options.
• **Employees:** Reduced headcount mentioned as a factor in lower SG&A expenses, indicating some workforce adjustments following divestitures. However, continued investment in R&D for pipeline candidates suggests ongoing opportunities in core oncology areas.
• **Creditors:** Positive impact from the repayment of substantially all of the $230 million 2026 Convertible Notes, significantly reducing the company's debt burden.

Next Steps

• Deepen LOQTORZI adoption within the community oncologist setting.
• Conduct Phase 1b CHS-114/toripalimab combination dose optimization studies in 2L head and neck (HNSCC) and 2L gastric cancers.
• Conduct Phase 1b study evaluating CHS-114/toripalimab combination, with and without chemotherapy, in 1L and 2L esophageal squamous cell carcinoma (ESCC).
• Continue enrollment in the Phase 2 randomized trial of casdozokitug/toripalimab/bevacizumab in 1L HCC.
• Anticipate initial data readouts for CHS-114 and casdozokitug in 1H 2026.
• Settle the $96.8 million in accrued rebates, fees, and reserves, primarily UDENYCA-related obligations, over the remainder of 2025 and into 2026.

Key Dates

Recommendation

The company demonstrates strong operational execution with a 36% quarter-over-quarter revenue growth for its key oncology product, LOQTORZI, which is gaining market traction. The strategic divestiture of UDENYCA has significantly bolstered the cash position to $237.6 million and enabled substantial debt reduction, extending the cash runway through 2026. This financial strengthening, combined with a focused oncology pipeline with key data readouts expected in 1H 2026, positions the company for potential future growth and derisks its development programs. While R&D expenses increased, this reflects investment in promising assets. The improved net loss from continuing operations further supports a positive outlook, suggesting the company is on a path to improved profitability in its core business.

Keywords

Oncology, Biotechnology, Pharmaceuticals, Cancer Treatment, LOQTORZI, Toripalimab, Nasopharyngeal Carcinoma, NPC, CHS-114, Casdozokitug, Immunotherapy, PD-1 Inhibitor, CCR8 Antibody, IL-27 Antagonist, Clinical Trials, Drug Development, Financial Results, SEC Filing, 8-K, Divestiture, Debt Repayment